Media coverage about Waters (NYSE:WAT) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Waters earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 47.6125064602481 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern’s analysis:

Several equities analysts recently weighed in on the company. Cleveland Research downgraded Waters from a “neutral” rating to an “underperform” rating in a research report on Thursday, June 14th. Morgan Stanley upped their price target on Waters from $200.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Friday, July 13th. Zacks Investment Research lowered Waters from a “buy” rating to a “hold” rating in a research note on Sunday, July 15th. Bank of America lowered Waters from a “neutral” rating to an “underperform” rating and set a $190.00 price target for the company. in a research note on Monday, July 16th. Finally, Robert W. Baird upped their price target on Waters from $201.00 to $212.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 25th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $206.27.

Shares of NYSE:WAT opened at $187.55 on Friday. The stock has a market cap of $14.64 billion, a price-to-earnings ratio of 25.04, a PEG ratio of 2.33 and a beta of 0.98. The company has a quick ratio of 5.95, a current ratio of 6.58 and a debt-to-equity ratio of 0.58. Waters has a 12 month low of $177.58 and a 12 month high of $220.20.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, July 24th. The medical instruments supplier reported $1.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.92 by $0.03. The company had revenue of $596.20 million during the quarter, compared to analyst estimates of $598.73 million. Waters had a return on equity of 27.85% and a net margin of 2.12%. The firm’s revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.76 earnings per share. research analysts predict that Waters will post 8.12 EPS for the current fiscal year.

Waters announced that its board has initiated a share repurchase plan on Tuesday, April 24th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 18.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

In other news, Director Joann A. Reed sold 2,090 shares of the stock in a transaction dated Tuesday, May 22nd. The stock was sold at an average price of $195.77, for a total value of $409,159.30. Following the completion of the sale, the director now owns 17,932 shares in the company, valued at $3,510,547.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael C. Harrington sold 15,000 shares of the stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $194.64, for a total value of $2,919,600.00. Following the completion of the sale, the senior vice president now owns 17,037 shares of the company’s stock, valued at approximately $3,316,081.68. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by company insiders.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Further Reading: Growth Stocks

Insider Buying and Selling by Quarter for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with's FREE daily email newsletter.